Stoke Therapeutics, Inc.
STOKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Stoke Therapeutics, Inc. (STOK) is listed under Biotechnology. The company carries a $1.81B market cap, placing it firmly in the small-cap category. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Market Cap
$1.81B
Beta
1.18
P/E (TTM)
—
P/E (Fwd)
-9.40
EPS (TTM)
$-2.86
EPS (Fwd)
$-3.09
ROE
-45.6%
ROA
-27.2%
Cash
$343.5M
Total Debt
$3.4M
Free CF
-$88.7M
52W Change
119.7%
Annual Financials
Cash vs Debt
Stoke Therapeutics, Inc. holds $343.5M in cash against $3.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$88.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -45.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $12.4M (2022) to $184.4M (2025), reflecting a 1387% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Stoke Therapeutics, Inc. and its sector.